Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: A pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 3, 2010, Pages 538-542

  de Kanter, C T M M ^a   Colbers, E P H ^a   Fillekes, Q ^a   Hoitsma, A ^a   Burger, D M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Generics; Lopinavir; Pharmacokinetics; Ritonavir

Indexed keywords

LOPIMUNE; LOPINAVIR PLUS RITONAVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; DRUG FORMULATION; DRUG GRANULE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINAL DYSMOTILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PILOT STUDY; SIDE EFFECT; SINGLE DRUG DOSE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMA; PYRIMIDINONES; RITONAVIR; YOUNG ADULT;

EID: 77950312688     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp472     Document Type: Article

References (9)

1. Palella FJJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. Gortmaker SL, Hughes M, Cervia J et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345: 1522-8.
3. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2009; 1-145. http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf (30 November 2009, date last accessed).
4. World Health Organization. Towards Universal Access. Scaling up Priority HIV/AIDS Interventions in the Health Sector. Progress Report 2009; 1-164. http://www.who.int/hiv/pub/tuapr_2009_en.pdf (30 November 2009, date last accessed).
5. Médecins Sans Frontières. Untangling the Web of Antiretroviral Price Reductions. 2008; 1-88. http://www.msfaccess.org/fileadmin/user_upload/diseases/hiv-aids/Untangling_the_Web/Untanglingtheweb_July_2008_English.pdf (11 August 2009, date last accessed).
6. L'homme RF, Dijkema T, Warris A et al. Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. J Antimicrob Chemother 2007; 59:92-6.
7. L'homme RF, Kabamba D, Ewings FM et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22: 557-65.
8. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25: 393-9.
9. Kaletra Oral Solution. Summary of Product Characteristics. 2006; 23-43. http://www.emea.europa.eu/humandocs/PDFs/EPAR/kaletra/emea-combined-h368en.pdf (11 August 2009, date last accessed).